文献速递角膜与眼表疾病

角膜血管化与一种新型PDGFRB变异相关

Corneal Vascularization Associated With a Novel PDGFRB Variant.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2023-01-01

本研究对一个表现角膜侵袭性血管化但其他方面健康的儿童家系进行外显子测序,发现PDGFRB基因新型变异c.1643C>A,p.(Ser548Tyr)。体外实验显示该变异在配体刺激下导致PDGFRβ过度活化,而多种酪氨酸激酶抑制剂可抑制这种过度活化,提示靶向治疗的可能性。

要点

  • 在一个孤立性角膜血管化家系中发现PDGFRB新型变异c.1643C>A,p.(Ser548Tyr)。
  • 该变异转导细胞在配体刺激后PDGFRβ磷酸化过度增加,提示信号通路过度活化。
  • 阿昔替尼、达沙替尼、伊马替尼和舒尼替尼在体外可抑制该变异受体的过度活化。

核心结论

  • 角膜血管化家系成员携带PDGFRB新型变异c.1643C>A,p.(Ser548Tyr)。
  • 该变异在配体刺激下导致PDGFRβ过度活化,可能引起角膜异常伤口愈合。
  • 所检测的酪氨酸激酶抑制剂可阻止这种过度活化,提示对这些患者进行靶向治疗的可能性。

研究设计与样本

  • 对受累家系成员进行外显子测序以寻找角膜血管化的遗传病因。
  • 用携带PDGFRB c.1643C>A,p.(Ser548Tyr)变异或野生型PDGFRB的HeLa细胞进行体外转导实验。
  • 采用ELISA和免疫印迹检测未处理及配体刺激细胞中PDGFRβ及下游信号蛋白的磷酸化水平。
  • 检测细胞对多种受体酪氨酸激酶抑制剂的敏感性。

主要发现

  • 在受累家系成员中发现新型PDGFRB变异c.1643C>A,p.(Ser548Tyr)。
  • 转导该变异的HeLa细胞基线磷酸化PDGFRβ水平未升高。
  • 配体刺激后,转导变异体的细胞较转导野生型的细胞显示PDGFRβ过度活化。
  • 携带p.(Ser548Tyr)氨基酸替换的PDGFRβ在体外可被阿昔替尼、达沙替尼、伊马替尼和舒尼替尼抑制。

临床怎么用

  • 作者认为所检测的酪氨酸激酶抑制剂在体外可阻止该变异引起的PDGFRβ过度活化,提出了对这些患者进行靶向治疗的可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to identify the genetic cause of aggressive corneal vascularization in otherwise healthy children in one family. Further, to study molecular consequences associated with the identified variant and implications for possible treatment. METHODS: Exome sequencing was performed in affected individuals. HeLa cells were transduced with the identified c.1643C>A, p.(Ser548Tyr) variant in the platelet-derived growth factor receptor beta gene (PDGFRB) or wild-type PDGFRB. ELISA and immunoblot analysis were used to detect the phosphorylation levels of PDGFRβ and downstream signaling proteins in untreated and ligand-stimulated cells. Sensitivity to various receptor tyrosine kinase inhibitors (TKIs) was determined. RESULTS: A novel c.1643C>A, p.(Ser548Tyr) PDGFRB variant was found in affected family members. HeLa cells transduced with this variant did not have increased baseline levels of phosphorylated PDGFRβ. However, upon stimulation with ligand, excessive activation of PDGFRβ was observed compared to cells transduced with the wild-type variant. PDGFRβ with the p.(Ser548Tyr) amino acid substitution was successfully inhibited with tyrosine kinase inhibitors (axitinib, dasatinib, imatinib, and sunitinib) in vitro. CONCLUSIONS: A novel c.1643C>A, p.(Ser548Tyr) PDGFRB variant was found in family members with isolated corneal vascularization. Cells transduced with the newly identified variant showed increased phosphorylation of PDGFRβ upon ligand stimulation. This suggests that PDGF-PDGFRβ signaling in these patients leads to overactivation of PDGFRβ, which could lead to abnormal wound healing of the cornea. The examined TKIs prevented such overactivation, introducing the possibility for targeted treatment in these patients.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Gladkauskas T, Bruland O, Abu Safieh L, et al. Corneal Vascularization Associated With a Novel PDGFRB Variant. Invest Ophthalmol Vis Sci. 2023. PMID: 37934158. doi:10.1167/iovs.64.14.9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。